Influenza AH1N1 2009 pneumonia in kidney transplant recipients: Characteristics and outcomes following high-dose oseltamivir exposure

Transplant Infectious Disease

Volumn 12, Issue 2, 2010, Pages 127-131

  Watcharananan, S P ^a   Suwatanapongched, T ^a   Wacharawanichkul, P ^b   Chantratitaya, W ^a   Mavichak, V ^b   Mossad, S B ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Praram 9 Hospital   (Thailand)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

H1N1; Influenza A; Kidney transplant; Oseltamivir; Pneumonia

Indexed keywords

AZITHROMYCIN; CEFEPIME; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; BRONCHOSCOPY; CASE REPORT; CHILL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DYSPNEA; EARLY INTERVENTION; FEVER; FLU LIKE SYNDROME; GRAFT RECIPIENT; GRAFT REJECTION; HEMODIALYSIS; HUMAN; HYPOXIA; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; LOW DRUG DOSE; LUNG LAVAGE; MALE; NOSE SMEAR; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHINORRHEA; SORE THROAT; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; VIRUS PNEUMONIA; INFLUENZA; KIDNEY TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; TRANSPLANTATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSELTAMIVIR; PNEUMONIA, VIRAL; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77950555049     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00493.x     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May 2009. MMWR Morb Mortal Wkly Rep 2009 58 (19) : 536 541.
2. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009 361 (7) : 680 689.
3. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009 58 (27) : 749 752.
4. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009 9 (8) : 493 504.
5. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine 2008 26 (Suppl 4) : D59 D66.
6. Guarner J, Paddock CD, Shieh WJ, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season. Clin Infect Dis 2006 43 (2) : 132 140.
7. Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003 40 : 304 310. (Pubitemid 38393580)
8. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets. Science 2009 325 (5939) : 481 483.
9. Maines TR, Jayaraman A, Belser JA, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009 325 (5939) : 484 487.
10. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009 58 (32) : 893 896.
11. Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2006 21 (9) : 2556 2562. (Pubitemid 44644531)
12. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999 37 (6) : 471 484. (Pubitemid 30032251)
13. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003 26 (11) : 787 801. (Pubitemid 37056109)
14. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000 355 (9218) : 1845 1850.
15. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003 51 (1) : 123 129. (Pubitemid 36163836)
16. Yoo Y, Sohn JW, Park DW, et al. Clinical evaluation of the SD bioline influenza virus antigen test for rapid detection of influenza viruses A and B in children and adults during the influenza season. Clin Vaccine Immunol 2007 14 (8) : 1050 1052.
17. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009 361 (7) : 728 729.
18. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009 361 (20) : 1945 1952.
19. Greenberg ME, Lai MH, Hartel GF, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine - preliminary report. N Engl J Med 2009 361 (25) : 2405 2413. (Epub 2009 September 10).
20. Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009 58 (RR-10) : 1 8.